Relationship between Brain Natriuretic Peptide and Thromboembolic Events in Elderly Patients with Nonvalvular Atrial Fibrillation

Relationship between Brain Natriuretic Peptide and Thromboembolic Events in Elderly Patients with Nonvalvular Atrial Fibrillation

Objective. To investigate the relationship between brain natriuretic peptide (BNP) and thromboembolic events in elderly patients with nonvalvular atrial fibrillation (NVAF). Methods. This is a prospective cohort study, and based on the inclusion and exclusion criteria, 180 elderly patients with NVAF...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hongxia Wang, Jiajun Huang, Wenxi Gu, Xiaojiao Hao, Guiru Li, Yumin Yuan, Yingmin Lu
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Cardiology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2024/5594637
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01)

Effect of drug interactions with non-vitamin-K oral anticoagulants on thromboembolic events in patients with nonvalvular atrial fibrillation
by: Jin-Hua Chen, et al.
Published: (2024-02-01)

Brain natriuretic peptide is a biomarker of atrial fibrillation in hemodialysis patients
by: Ling Yu, et al.
Published: (2025-12-01)

Thromboembolic risk factors and predictors of left atrial appendage thrombosis in Far North patients with nonvalvular atrial fibrillation
by: N. Yu. Khorkova, et al.
Published: (2021-11-01)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016-01-01)

CHANGES IN THE LEVEL OF NATRIURETIC PEPTIDES IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ANTIARRHYTHMIC DRUGS
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

THE SELECTION PROBLEMS OF ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION WITH COMORBIDITIES
by: N. A. Koziolova, et al.
Published: (2015-08-01)

Relationship between the type of atrial fibrillation and thromboembolic events
by: Potpara Tatjana, et al.
Published: (2009-01-01)

Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
by: Jean Michell Correia Monteiro, et al.

Predictors of Thrombus Dissolution in the Left Atrial Appendage in Patients with Persistent Nonvalvular Atrial Fibrillation
by: E. S. Mazur, et al.
Published: (2022-03-01)

Fibrosis biomarkers as predictors of left atrial appendage thrombosis in patients with nonvalvular atrial fibrillation
by: T. P. Gizatulina, et al.
Published: (2022-08-01)

Predictors of spontaneous echo contrast and left atrial appendage thrombosis in nonvalvular atrial fibrillation
by: N. Yu. Khorkova, et al.
Published: (2020-08-01)

COMPARISON OF THE EFFECTS OF FOUR ANTIHYPERTENSIVE THERAPY VARIANTS ON ARTERIAL WALL ELASTICITY IN ELDERLY PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
by: V. I. Shevelev, et al.
Published: (2013-08-01)

Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation
by: Catherine J. Mercaldi, et al.
Published: (2012-01-01)

ENDOVASCULAR METHODS FOR CLOSURE OF THE LEFT ATRIAL APPENDAGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION FOR STROKE PREVENTION
by: R. V. Guchaev, et al.
Published: (2018-05-01)

PRACTICAL CONCERNS OF ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION: A UNIVERSITY CLINICS REGISTRY
by: A. A. Sokolova, et al.
Published: (2015-09-01)

Predictive Value of Blood and Echocardiographic Indicators for Nonvalvular Atrial Fibrillation in Postmenopausal Women
by: Lei Song, et al.
Published: (2025-03-01)

Anticoagulation control for nonvalvular atrial fibrillation in a tertiary academic centre in Johannesburg
by: Vanessa Mogashoa, et al.
Published: (2024-10-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

N-terminal pro-B-type Natriuretic peptide levels and left atrial appendage thrombosis in patients with persistent atrial fibrillation
by: Chien Do Van, et al.
Published: (2023-11-01)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
by: Raffaele De Caterina, et al.
Published: (2019-03-01)

Construction of a Clinical Predictive Model of Left Atrial and Left Atrial Appendage Thrombi in Patients with Nonvalvular Atrial Fibrillation
by: Lei Yin, et al.
Published: (2022-01-01)

AGE AND EFFECTIVENESS AND SAFETY OF VARIOUS ANTITHROMBOTIC THERAPY VARIANTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
by: V. I. Shevelev, et al.
Published: (2013-02-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile
by: Tomás Abbot, et al.
Published: (2025-07-01)

THE ENDOVASCULAR PREVENTION OF THROMBOEMBOLISM IN ATRIAL FIBRILLATION
by: Rami N. Al-Ayyubi, et al.
Published: (2018-12-01)

Construction and validation of a nomogram for predicting 3-month outcome in elderly patients with nonvalvular atrial fibrillation-induced acute ischemic stroke
by: Yang Yang, et al.
Published: (2025-05-01)

Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic
by: A. S. Polyakov, et al.
Published: (2021-09-01)

Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
by: A.V. Fonyakin
Published: (2014-06-01)

Hospitalization trends for thromboembolic events in atrial fibrillation: A 12-year national analysis
by: Moises A. Vasquez, et al.
Published: (2025-09-01)

Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.
by: Alyaa M Ajabnoor, et al.
Published: (2022-06-01)

Predicting of Long-term Maintenance of Sinus Rhythm after Cardioversion in Patients with Nonvalvular Persistent Atrial Fibrillation
by: Zharinov O., et al.
Published: (2014-12-01)

Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy
by: E. S. Mazur, et al.
Published: (2021-11-01)

Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation
by: Shigeki Kobayashi, et al.
Published: (2025-02-01)

Effect of low-dose rivaroxaban on bleeding events in low-weight patients with nonvalvular atrial fibrillation: a retrospective propensity score-matched cohort study
by: Yuan Liu, et al.
Published: (2024-11-01)

THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS
by: I. A. Zaigrayev, et al.
Published: (2020-01-01)

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER
by: I. S. Yavelov
Published: (2016-01-01)

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies
by: Bo Cao, et al.
Published: (2021-01-01)

Predictive thresholds of peak and trough anti-Xa levels for bleeding risk in rivaroxaban-treated nonvalvular atrial fibrillation
by: Mouhammad Rida Almouwannes, et al.
Published: (2025-08-01)